| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
25,930 |
21,861 |
$2.23M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,067 |
6,168 |
$866K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,900 |
3,544 |
$413K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,824 |
2,554 |
$277K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,427 |
2,221 |
$254K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,264 |
3,798 |
$184K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
9,963 |
8,766 |
$123K |
| 87428 |
|
4,129 |
3,621 |
$119K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
732 |
657 |
$85K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,824 |
3,131 |
$76K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,331 |
1,173 |
$71K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
4,202 |
3,333 |
$67K |
| D1206 |
Topical application of fluoride varnish |
2,153 |
2,147 |
$55K |
| 90686 |
|
1,833 |
1,763 |
$41K |
| 90648 |
|
1,609 |
1,450 |
$36K |
| 90670 |
|
1,247 |
1,176 |
$28K |
| 87807 |
|
2,099 |
1,805 |
$23K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
449 |
403 |
$20K |
| 90723 |
|
795 |
733 |
$18K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,574 |
1,368 |
$16K |
| 96127 |
|
3,178 |
2,821 |
$15K |
| 90677 |
|
385 |
342 |
$8K |
| 96160 |
|
2,797 |
2,499 |
$7K |
| 92552 |
|
265 |
247 |
$6K |
| 90656 |
|
320 |
300 |
$6K |
| 99051 |
|
333 |
276 |
$6K |
| 90633 |
|
190 |
166 |
$4K |
| 96161 |
|
1,564 |
1,403 |
$4K |
| 0071A |
|
106 |
100 |
$4K |
| 0002A |
|
95 |
94 |
$4K |
| 0072A |
|
96 |
90 |
$4K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
317 |
272 |
$4K |
| 83655 |
|
299 |
264 |
$3K |
| 0001A |
|
86 |
83 |
$3K |
| 90681 |
|
118 |
110 |
$3K |
| 92551 |
|
247 |
223 |
$2K |
| 90651 |
|
60 |
42 |
$1K |
| 90647 |
|
56 |
52 |
$1K |
| 90734 |
|
47 |
42 |
$1K |
| 80061 |
Lipid panel |
78 |
71 |
$942.11 |
| 3008F |
|
3,709 |
3,289 |
$685.03 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
56 |
52 |
$575.50 |
| 85018 |
|
256 |
226 |
$568.40 |
| W7000 |
|
114 |
110 |
$555.72 |
| 99177 |
|
108 |
95 |
$535.70 |
| 99173 |
|
130 |
122 |
$336.77 |
| 81002 |
|
84 |
65 |
$201.12 |
| A7015 |
Aerosol mask, used with dme nebulizer |
57 |
52 |
$85.25 |
| 94760 |
|
33 |
31 |
$49.66 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
240 |
207 |
$29.01 |
| 36416 |
|
425 |
383 |
$19.50 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
652 |
565 |
$0.01 |
| INVCD |
|
39 |
39 |
$0.00 |